The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.
about
Which anticholinergic drug for overactive bladder symptoms in adultsInhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitisMirabegron: a review of recent data and its prospects in the management of overactive bladderOveractive bladder: strategies to ensure treatment compliance and adherenceIntravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract SurgeryBotulinum toxin A for the Treatment of Overactive BladderPersistence and compliance with medication management in the treatment of overactive bladderClinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndromeFlexible dosing with fesoterodine 4 and 8 mg: a systematic review of data from clinical trialsThe pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder diseaseOveractive bladder syndrome: Current pathophysiological concepts and therapeutic approachesAdverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approachCost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder.Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.Treating Diabetic Neuropathy: Present Strategies and Emerging Solutions.Effects of duloxetine and WAY100635 on pudendal inhibition of bladder overactivity in cats.CUA guideline on adult overactive bladderDose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinenceCost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.Effectiveness of combined high-dosed trospium and solifenacin depending on severity of OAB symptoms in elderly men and women under cyclic therapy.Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)Urinary incontinence in women: part 1 of a series of articles on incontinence.To what extent are national guidelines for the management of urinary incontinence in women adhered? Data from a national audit.Inhaled anticholinergic drugs and risk of acute urinary retention.Urinary incontinence in the elderly: part 3 of a series of articles on incontinenceThe surgical management of the refractory overactive bladder.Medical management of overactive bladderRecent advances in management of bladder overactivity.The placebo effect in overactive bladder syndrome.Single compartment drug delivery.Izalpinin from fruits of Alpinia oxyphylla with antagonistic activity against the rat bladder contractilityEfficacy and safety of ginger-salt-indirect moxibustion for urge urinary incontinence after stroke: protocol for a pilot multicentre randomised controlled trial.Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency.Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient complianceTolterodine extended-release for overactive bladder.Emerging drugs for treatment of urinary incontinence.Mirabegron: a safety review.Mirabegron - a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
P2860
Q24203880-66D4F456-4E91-4608-86B1-3C0B881D0DE4Q24614844-C6856ADA-C3EB-4CD4-A536-A543C538F655Q24617239-55F407C8-ED65-40A4-AFCA-3F60F9424BF5Q26746914-FB60F861-4D80-4502-89A2-C29FEB24A1BAQ26749608-F8625787-27E7-4130-B9D1-4A72F977B562Q26764765-1D3E5C4E-E112-4946-B1F8-C685EC270E1EQ26765014-39835F78-AAA9-4B83-ADEA-F8A4295B8955Q26783536-3A9D90E7-6545-487F-AE3B-22B57375A571Q26827108-B6C1B1E0-4A4D-4B66-92D4-55806528F68EQ26864937-76AD908C-F838-4B4B-BB41-736724EC8E97Q27022279-2C3A6F57-9DCE-4508-A9DE-896CE795A491Q28742444-41F45908-2D01-46FE-A48F-E4AF3A5AD520Q31013378-A2DBA110-AB85-41B5-A928-16F8AA9FC035Q33485538-51C949F0-810A-4873-8C98-03FB902AB3E8Q33515909-A28216B4-82C7-4B53-80A1-03604CA4385EQ33583006-49475675-18BE-443B-A65C-28EB2A7A1E12Q33603621-558B30D5-9519-4492-917F-6E50C7FDDFAAQ33665026-D59F06AB-A086-4F4B-B649-2842E146EBDCQ33692394-9B1E1178-7AC9-4FEE-A0AF-FEFD16B760A5Q33696642-AC1B4828-4523-438C-AD09-721E0070B973Q33819939-2622B88E-6653-4B25-860B-3CDCDED2F701Q33835874-2887BEDE-3387-40E2-8617-C81A4BDC60DEQ33961553-5EA24B19-36CC-4054-8832-E8D3B77FA64AQ34012234-B6B9D1AF-9BFE-48E3-8FA7-729822D9A83AQ34024144-65FC359F-453C-4A46-877E-516252121CDCQ34078299-CC959D1A-C40F-4E8A-8B60-B648B39FD60BQ34124059-FCA4B14A-A16D-4057-BCBD-75EFED7C7975Q34124065-21761DA9-72BF-4997-9120-A3B3ABFB8CE7Q34167658-399630C4-E554-449B-B144-50F883A26822Q34197411-BE0CD32A-4F78-4FD8-8ECC-852B2C16AF17Q34263907-30A6905E-5A2A-468C-9066-4C2434C63CA3Q34367187-3D66CCD2-9F39-44F7-81FF-C5D795A055DAQ34397227-3296F04E-CD9B-4EDA-A7C6-E6CD1907CAB5Q34405906-943AC0A2-6504-4117-A1B8-B727E7C7D822Q34524320-E692C1BF-0728-40F2-97D2-3BC921472C05Q34536721-2AD8DC6F-4AB7-4402-99C5-303E63B53428Q34610640-B294E748-09EE-4948-8AA6-5D1D7B81889AQ34618648-C245CF43-BF2E-4D49-A6C3-1A7D62EB866BQ34625687-670DD93B-E8F6-4337-9A7E-59FCC1835D2EQ34657220-B47FF6B0-03BA-4A89-927C-428CB1E8D563
P2860
The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The effects of antimuscarinic ...... atic review and meta-analysis.
@en
The effects of antimuscarinic ...... atic review and meta-analysis.
@nl
type
label
The effects of antimuscarinic ...... atic review and meta-analysis.
@en
The effects of antimuscarinic ...... atic review and meta-analysis.
@nl
prefLabel
The effects of antimuscarinic ...... atic review and meta-analysis.
@en
The effects of antimuscarinic ...... atic review and meta-analysis.
@nl
P2093
P1433
P1476
The effects of antimuscarinic ...... atic review and meta-analysis.
@en
P2093
Caty Ebel Bitoun
David Weinstein
Dominic Muston
Vik Khullar
Zahava Gabriel
P304
P356
10.1016/J.EURURO.2008.06.047
P407
P577
2008-06-20T00:00:00Z